A Glimpse Into The Expert Outlook On Enanta Pharma Through 4 Analysts
Portfolio Pulse from Benzinga Insights
Enanta Pharma (NASDAQ:ENTA) has received mixed analyst ratings over the past three months, with a current average price target of $20.25. Analysts have expressed both bullish and bearish views, with recent actions including maintaining and lowering ratings. Enanta faces financial challenges, including a decline in revenue and below-average profitability metrics.
October 09, 2024 | 7:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Enanta Pharma has received mixed analyst ratings, with a current average price target of $20.25. The company faces financial challenges, including a decline in revenue and below-average profitability metrics.
The mixed analyst ratings indicate uncertainty in the market's perception of Enanta Pharma. The company's financial challenges, such as declining revenue and poor profitability metrics, contribute to this uncertainty. The average price target has slightly decreased, reflecting cautious sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100